Foto: Thomas Peter/Reuters/Ritzau Scanpix

Genmab gets new MS market rival after fresh FDA approval

TG Therapeutics enters the lucrative market for multiple sclerosis treatment with newly approved drug Briumvi, now in line to compete with Genmab and Novartis’ Kesimpta and Roches Ocrevus.

For subscribers

Henrik Juuel, CFO at Bavarian Nordic. | Foto: Bavarian Nordic / Pr

Bavarian CFO eyes breakeven chance in this year's decisive final days

Coloplast agrees to million-dollar settlement in the US

For subscribers

Novo Nordisk overtakes giants in market value

Despite new diabetes treatments, Novo Nordisk predicts long-term success for insulin

"We’re building a team, we already have a well founded set-up, and we’re already testing every procedure and system, because this will be the most important milestone of the year,” says van de Winkel. | Foto: PR / Genmab

CEO Jan van de Winkel: New cancer drug is Genmab's most important milestone next year

For subscribers

US won’t back 2022 patent waivers for Covid tests and treatments
The US joins nearly three dozen nations in seeking more time and information about a potential waiver extension.
For subscribers
Companies must avoid pitfalls of new patent system, advisors warn
From next year onwards, companies will be able to launch patent applications through a shared European court. That comes with opportunities, but there are risks as well, say lawyers and advisors.
For subscribers
Britt Meelby Jensen: Ambu must adjust itself
Ambu CEO Britt Meelby Jensen wants to get closer to customers and strengthen the company’s ability to shift course while in motion, she says ahead of unveiling a new strategy.
For subscribers
Nouveau riche Bavarian Nordic to grow "slightly thin" pipeline
The Danish biotech firm’s pipeline is ”slightly thin” when omitting Covid-19 and RSV, concedes CFO Henrik Juuel, revealing that the vaccine maker will thus from next year push new assets into the pipeline addressing infectious diseases.
For subscribers
Bavarian Nordic's Q3 revenue exceeds DKK 1bn
The Danish biotech firm’s Q3 report released Wednesday morning shows the top line surpassing DKK 1bn, however skimming thin operating earnings.
For subscribers
Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play
William Demant Invest has extended its equity position in GN Store Nord to at least 10%, and whereas the Danish investment firm’s CEO says this move is wholly in line with company strategy, several analysts question the motives behind the purchase.
For subscribers
GN rebrands US acquisition
Online retailer Lively changes name as a part of integrating with GN, which purchased the US-based company in 2021.
For subscribers
CHMP has approved nine medications during June
The European authority’s expert committee has now approved a total of 47 medications during 2022.
For subscribers
Ambu recalls resuscitation product
The Danish company is recalling a resuscitation product, reports Bloomberg News after a Danish Medicines Authority announcement.
For subscribers
Sanofi pivots toward boosters after Covid vaccine delays
Sanofi ends development of Covid Messenger-RNA vaccine.
For subscribers
Sanofi's big dermatology hope fails in phase III
One of the drugs Sanofi had otherwise imagined would become one of the stars in the autoimmune medication portfolio has flunked out of phase III trials as a treatment for skin disease pemfigus.
For subscribers
Danish government wants to spend USD 160m on permanent research and development tax deduction
In a reform proposal on Tuesday, the Danish government announced plans to make the 130 percent raised tax deduction on research and development permanent. A cap on the tax value of individual companies will still be in place, however.
For subscribers
Astrazeneca and EU settle missing vaccines case
The case of the missing delivery of Covid-19 vaccines won't make it to court as the two parties agree to settle.
For subscribers
Pfizer goes head to head with Sanofi's multi-blockbuster with new study data
A new phase III study conducted by Pfizer comparing its drug abrocitinib with Sanofi best-seller Dupixent favors the former's medicine.
New factory takes AGC Danmark to another level within the corporation
Demand for medication production is now so high that AGC Biologics' Danish unit expects to sell the output of almost full production capacity at the company's new factory within three years after commissioning, expectedly in 2023.
For subscribers
Lundbeck introduces vaccine requirement for US staff
The Danish pharmaceutical firm is the latest of several companies operating in the US to close its doors to unvaccinated personnel.
For subscribers
Novo Nordisk after US delivery issues: New obesity drug launch set for H2 next year
It is not just in the US that significant demand for Novo Nordisk's obesity drug Wegovy is having an impact. The pharmaceutical firm now reports that new launches of the drug will not take place until during the second half of 2022.
For subscribers
FDA approves Ascendis' weekly growth hormone
A growth hormone for weekly use made by Denmark's Ascendis Pharma may now be commercialized in the US after the public authority approved the company's treatment, Skytrofa.
For subscribers
Delayed Danish state Covid vaccine to be trialled on humans in 2022
National Danish infectious disease research organization Statens Serum Institut has found a manufacturer for its in-house Covid-19 vaccine, moving it closer to testing the candidate on human subjects following a series of delays.
For subscribers
Bavarian Nordic initiates phase II trial for Covid-19 vaccine
In a long-awaited phase II trial, Bavarian Nordic starts testing the efficacy of its Covid-19 vaccine for reinforcing existing immunity in persons either previously vaccinated or infected.
For subscribers

Latest news

See all

Jobs

See all jobs

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Genmab gets new MS market rival after fresh FDA approval

Bavarian CFO eyes breakeven chance in this year's decisive final days

Coloplast agrees to million-dollar settlement in the US

Novo Nordisk overtakes giants in market value

Despite new diabetes treatments, Novo Nordisk predicts long-term success for insulin

CEO Jan van de Winkel: New cancer drug is Genmab's most important milestone next year

US won’t back 2022 patent waivers for Covid tests and treatments

Companies must avoid pitfalls of new patent system, advisors warn

Britt Meelby Jensen: Ambu must adjust itself

Nouveau riche Bavarian Nordic to grow "slightly thin" pipeline

Bavarian Nordic's Q3 revenue exceeds DKK 1bn

Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play

GN rebrands US acquisition

CHMP has approved nine medications during June

Ambu recalls resuscitation product

Sanofi pivots toward boosters after Covid vaccine delays

Sanofi's big dermatology hope fails in phase III

Danish government wants to spend USD 160m on permanent research and development tax deduction

Astrazeneca and EU settle missing vaccines case

Pfizer goes head to head with Sanofi's multi-blockbuster with new study data

New factory takes AGC Danmark to another level within the corporation

Lundbeck introduces vaccine requirement for US staff

Novo Nordisk after US delivery issues: New obesity drug launch set for H2 next year

FDA approves Ascendis' weekly growth hormone

Delayed Danish state Covid vaccine to be trialled on humans in 2022

Bavarian Nordic initiates phase II trial for Covid-19 vaccine

Latest news

Jobs